跳至主要内容
临床试验/CTRI/2010/091/002815
CTRI/2010/091/002815尚未招募1 期

An open-label, randomized, single-dose, two-treatment,two-sequence, three-period, replicate crossover study todetermine the bioequivalence of SPP100 300 mg tablets(aliskiren) (small tablet vs. marketed formulation) in healthyadult volunteers

ovartis Healthcare Pvt. Ltd.Raheja IT Park, Mind Space - Bld # 6, Hitech City,Village - Madhapur,Hyderabad 500081, India0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Healthy male and female subjects age 18 to 55 years
  • Subjects must weigh at least 50 kg and BMI within 18 to 30 kg/m2
  • Able to communicate well with the investigator,

排除标准

  • Smokers who report cigarette use of more than 5 cigarettes per day.
  • Subjects who use any prescription drugs, herbal supplements, OTC drugs or diet suppliments
  • A past medical history of clinically significant ECG abnormalities.

研究者

发起方
ovartis Healthcare Pvt. Ltd.Raheja IT Park, Mind Space - Bld # 6, Hitech City,Village - Madhapur,Hyderabad 500081, India

相似试验